Convalescent plasma for SARS-CoV-2 infection: win or learn

Enric Contreras-Barbeta, Anna Millan, Jordi Rello

Source: Eur Respir J, 59 (2) 2102076; 10.1183/13993003.02076-2021
Journal Issue: February

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Enric Contreras-Barbeta, Anna Millan, Jordi Rello. Convalescent plasma for SARS-CoV-2 infection: win or learn. Eur Respir J, 59 (2) 2102076; 10.1183/13993003.02076-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Management of COVID-19: Other drugs and convalescent plasma
Source: ERS Course 2021 - COVID-19: State of the art
Year: 2021

Is it just an infection?
Source: Breathe, 14 (3) e100; 10.1183/20734735.021518
Year: 2018



Latent TB: what's next?
Source: Annual Congress 2007 - Latent tuberculosis: what's next?
Year: 2007

Patients with recurrent tuberculosis in Istanbul: reactivation?, reinfection?
Source: International Congress 2018 – Diagnosis of tuberculosis
Year: 2018


Pathology: what do we actually want to know?
Source: Annual Congress 2008 - Multidisciplinary approach in interstitial lung disease
Year: 2008


Keynote lecture: Immunodiagnosis of tuberculosis - are we asking for too much?
Source: Annual Congress 2011 - What is new in tuberculosis immunodiagnosis?
Year: 2011

How much time does urinary legionella antigen excretion need to be negative in an outbreak?
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007



A tale of two global emergencies: tuberculosis control efforts can learn from the Ebola outbreak
Source: Eur Respir J 2015; 46: 293-296
Year: 2015


Lung sarcoidosis in HIV infection: myth or reality?
Source: Virtual Congress 2021 – Rare thoracic surgical disease and the chest wall
Year: 2021


Why do we need to vaccinate against pneumonia?
Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination?
Year: 2014

Late Breaking Abstract - Impact of COVID-19 social distancing on viral infection in France: a delayed outbreak of RSV
Source: Virtual Congress 2021 – Acute and chronic lung infections in children
Year: 2021



TB vaccination: why, when, how and what?
Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults
Year: 2014




Is neopterin concentration predictive in latent tuberculosis infection in health workers?
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis I
Year: 2008

Screening migrants for tuberculosis and latent TB infection: the reward will come later
Source: Eur Respir J, 54 (4) 1901719; 10.1183/13993003.01719-2019
Year: 2019



Should we treat every patient with latent TB? Is there a cost to pay?
Source: International Congress 2018 – Tuberculosis transmission and screening strategies
Year: 2018



What do they know about TB?
Source: Eur Respir J 2002; 20: Suppl. 38, 163s
Year: 2002

Influenza news from the frontline: what's happening?
Source: ERJ Open Res, 4 (1) 00020-2018; 10.1183/23120541.00020-2018
Year: 2018



How contagious are the new viruses and how can you protect yourself?
Source: Annual Congress 2005 - Major viral threats to the lung
Year: 2005

Pleural infection: are we getting it right?
Source: International Congress 2019 – PG15 Management of pleural disease in 2019: applying the evidence
Year: 2019